• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immun Ageing . Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and het

tetano

Editor, Senior Moderator
Immun Ageing


. 2023 May 11;20(1):20.
doi: 10.1186/s12979-023-00344-w. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice

Bo Ryoung Park[SUP] 1 [/SUP], Ramireddy Bommireddy[SUP] 2 [/SUP], David Hyunjung Chung[SUP] 1 [/SUP], Ki-Hye Kim[SUP] 1 [/SUP], Jeeva Subbiah[SUP] 1 [/SUP], Yu-Jin Jung[SUP] 1 [/SUP], Noopur Bhatnagar[SUP] 1 [/SUP], Christopher D Pack[SUP] 3 [/SUP], Sampath Ramachandiran[SUP] 3 [/SUP], Shaker J C Reddy[SUP] 3 [/SUP], Periasamy Selvaraj[SUP] 2 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP]



Affiliations
Abstract

Background: Current influenza vaccines deliver satisfactory results in young people but are less effective in the elderly. Development of vaccines for an ever-increasing aging population has been an arduous challenge due to immunosenescence that impairs the immune response in the aged, both quantitatively and qualitatively.
Results: To potentially enhance vaccine efficacy in the elderly, we investigated the immunogenicity and cross-protection of influenza hemagglutinin virus-like particles (HA-VLP) incorporated with glycosylphosphatidylinositol (GPI)-anchored cytokine-adjuvants (GPI-GM-CSF and GPI-IL-12) via protein transfer in aged mice. Lung viral replication against homologous and heterologous influenza viruses was significantly reduced in aged mice after vaccination with cytokine incorporated VLPs (HA-VLP-Cyt) in comparison to HA-VLP alone. Enhanced IFN-γ[SUP]+[/SUP]CD4[SUP]+[/SUP] and IFN-γ[SUP]+[/SUP]CD8[SUP]+[/SUP] T cell responses were also observed in aged mice immunized with HA-VLP-Cyt when compared to HA-VLP alone.
Conclusions: Cytokine-adjuvanted influenza HA-VLP vaccine induced enhanced protective response against homologous influenza A virus infection in aged mice. Influenza HA-VLP vaccine with GPI-cytokines also induced enhanced T cell responses correlating with better protection against heterologous infection in the absence of neutralizing antibodies. The results suggest that a vaccination strategy using cytokine-adjuvanted influenza HA-VLPs could be used to enhance protection against influenza A virus in the elderly.

Keywords: Aged mice; Cross protection; Cytokine adjuvants; GPI-GM-CSF; GPI-IL-12; HA-VLP; Hemagglutinin (HA); Influenza; T cells; Virus-like particles (HA-VLPs).

 
Back
Top Bottom